在急性心肌梗塞患者中预测心脏性休克,使用诺莫图
Jie Wang1, Changying Zhao2, Chuqing Yang3
1Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an 710061, China.
Journal of clinical medicine
|December 30, 2025
概括
这项研究确定了急性心肌梗塞患者入院时心脏性休克的七个关键风险因素. 一个新的预测模型可以帮助医生早期识别高风险个体,以获得更好的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 临床预测模型临床预测模型
背景情况:
- 急性心肌梗塞 (AMI) 后的心脏性休克 (CS) 具有很高的死亡率.
- 早期识别患有住院CS风险的患者对于及时干预至关重要.
- 这项研究的重点是使用入学数据开发一个预测模型.
研究的目的:
- 开发和验证急性心肌梗塞患者在医院内心脏性休克的风险预测模型.
- 在入院时确定心脏性休克的独立风险因素.
- 为临床决策创建一个名图.
主要方法:
- 追溯病例控制研究设计.
- 根据年龄,性别和ST升高心肌梗塞诊断的倾向性得分匹配 (1: 1).
- 利用放松的最小绝对收缩和选择操作员和多变量后勤回归来确定独立的风险因素.
主要成果:
- 在AMI患者中发现了七个独立的CS风险因素:静脉血压,静脉血压,甘油三,肌素,血球蛋白,左心室喷射分数和冠状动脉血管学.
- 开发的名图表显示出强大的区分能力,曲线下的面积为0.937.
- 该模型显示了良好的校准和决策曲线分析结果.
结论:
- 在急性心肌梗塞患者的入院时,确定了七个独立的心脏性休克风险因素.
- 开发的诺米图可以帮助AMI患者早期风险分层.
- 这种工具可以改善临床决策和患者的治疗结果.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
360
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
360
Heart Failure I: Introduction
657
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
657
Acute Coronary Syndrome III: Diagnostic Studies
194
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
194
Cardiomyopathy VI: Nursing Management
289
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
289
Cardiomyopathy II: Dilated Cardiomyopathy
431
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431
Cardiopulmonary Resuscitation IV: Pharmacological Management
570
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
570


